Related Experiment Video
Updated: Jun 5, 2025

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis
Kazuma Yamakawa1, Kohji Okamoto2, Yoshinobu Seki3
1Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan. kazuma.yamakawa@ompu.ac.jp.
Insights
New Japanese guidelines offer recommendations for diagnosing and treating disseminated intravascular coagulation (DIC) in sepsis patients. Antithrombin and recombinant thrombomodulin are recommended, while heparin and serine protease inhibitors lack sufficient evidence for clear guidance.
Area of Science:
- Hematology
- Critical Care Medicine
- Clinical Guidelines
Background:
- The Japanese Society on Thrombosis and Hemostasis (JSTH) previously issued DIC guidelines in 2009.
- Updated guidelines address DIC in various conditions, including sepsis, using the GRADE system for evidence assessment.
Purpose of the Study:
- To present Part 1 of the JSTH's updated DIC guidelines, focusing on sepsis-associated DIC.
- To provide evidence-based recommendations for diagnosis and pharmacotherapy in DIC patients with sepsis.
Main Methods:
- Systematic review of evidence using the GRADE system.
- Formulation of clinical questions regarding DIC diagnosis and treatment in sepsis.
- Development of recommendations based on the certainty of evidence.
Main Results:
- Recommends selecting appropriate diagnostic criteria (e.g., JAAM-2, ISTH, SIC, JSTH DIC) based on their properties.
- Strongly recommends antithrombin (GRADE 1B) and recombinant thrombomodulin (GRADE 1B) for pharmacotherapy in sepsis-associated DIC.
- No clear recommendation for heparin or serine protease inhibitors due to insufficient evidence.
Conclusions:
- Highlights the importance of choosing suitable diagnostic criteria for DIC in sepsis.
- Supports the use of antithrombin and recombinant thrombomodulin in managing sepsis-induced DIC.
- Identifies combination therapy and administration methods for antithrombin and recombinant thrombomodulin as key areas for future research.
Abstract:
The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Acute Pancreatitis II: Clinical Manifestations and Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Standards of Care II
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

